Aldehyde dehydrogenase, a therapeutic target in chordoma: Analysis in 3d cellular models

4Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Chordomas are rare, slow-growing tumors of the axial skeleton. These tumors are locally aggressive and refractory to conventional therapies. Radical surgery and radiation remain the first-line treatments. Despite these aggressive treatments, chordomas often recur and second-line treatment options are limited. The mechanisms underlying chordoma radioresistance remain unknown, although several radioresistant cancer cells have been shown to respond favorably to aldehyde de-hydrogenase (ALDH) inhibition. The study of chordoma has been delayed by small patient cohorts and few available models due to the scarcity of these tumors. We thus created cellular 3D models of chordoma by using low-adherence culture systems. Then, we evaluated their radiosensitivity using colony-forming and spheroid size assays. Finally, we determined whether pharmacologically inhibiting ALDH increased their radiosensitivity. We found that 3D cellular models of chordoma (derived from primary, relapse, and metastatic tumors) reproduce the histological and gene expression features of the disease. The metastatic, relapse, and primary spheroids displayed high, me-dium, and low radioresistance, respectively. Moreover, inhibiting ALDH decreased the radiore-sistance in all three models.

Cite

CITATION STYLE

APA

Locquet, M. A., Dechaume, A. L., Berchard, P., Abbes, L., Pissaloux, D., Tirode, F., … Dutour, A. (2021). Aldehyde dehydrogenase, a therapeutic target in chordoma: Analysis in 3d cellular models. Cells, 10(2), 1–21. https://doi.org/10.3390/cells10020399

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free